Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q2 2026 Earnings Presentation
10 slides from Avita Medical's earnings presentation, Aug 6, 2026
Slide 1: Second Quarter 2026 Financial and Business Update
Second Quarter 2026 Financial and Business Update August 6, 2026
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: Commercial execution drives strong second quarter revenue and higher forecast
Commercial execution drives strong second quarter revenue and supports higher revenue forecast and path to cash flow breakeven in 2026 Net revenue Portfolio quarter-over-quarter in USD millions in USD millions Q1 2026 Q2 2026 US RECELL $16.6 $18.5 ~11% Cohealyx $1.5 $1.7 ~16% $18.4 $17.1 $17.6 $19.3
Slide 4: Revenue growth continues to lead positive change in financials
Revenue growth continues to lead positive change in financials Key figures Q2 Q2 Change vs PY Q1 Change vs Q1 in USD millions 2026 2025 2026 Revenue $21.7 $18.4 +18% $19.3 +13% Gross profit margin 81.9% 81.2% +70 BPS 81.7% +20 BPS Operating expenses $24.6 $26.1 +5.8% $24.5 n/a Net loss ($7.7) ($9.9)
Slide 5: Clear trajectory to cash flow breakeven in 2026
Clear trajectory to cash flow breakeven in 2026 Revenue Growth Gross margin Operating Expense in USD millions in USD millions Full year forecast: $21.7 $86-89 $24.7 $24.5 $24.6 $19.3 81.2% 81.7% 81.9% $17.6 ~13% QoQ ~10% Q4 Q1 Q2 Q4 Q1 Q2 QoQ 2025 2025 Q4 Q1 Q2 2025 Sequential growth towards Sustain
Slide 6: Balance sheet supports our 2026 outlook
Balance sheet supports our 2026 outlook Updated full year 2026 guidance Net Revenue expected to grow: Expect to achieve cash flow breakeven in: $86M to $89M Q4 2026 Balance sheet outlook Liquidity Covenant Confidence Financial Flexibility Liquidity supports Minimum cash and trailing 12- $10 million
Slide 7: RECELL utilization continues to strengthen as physician adoption expands
RECELL utilization continues to strengthen as physician adoption expands Total U.S. RECELL Volume by Quarter RECELL GO mini cases by wound size (2026 YTD) in cm2 in units 43% +10.3% +12.5% +1.5% 34% 2,621 11% 2,341 2,376 7% +3% Q4 2025 Q1 2026 Q2 2026 <300 301-500 501-800 801-1920 >1921 Includes REC
Slide 8: New 2027 SCSA CPT Code family streamlines RECELL procedure reporting
New 2027 SCSA CPT Code family streamlines RECELL procedure reporting 2027 SCSA CPT Code family improves coding clarity and supports proposed national physician valuation framework Key improvements in the new code structure Bundles harvest, preparation, and application Why the valuation framework mat
Slide 9: Entering the second half 2026 a stronger, predictable business
Entering the second half 2026 a stronger, predictable business Commercial Financial Outlook Record quarterly Raised 2026 revenue High gross margin revenue guidance All three products Q4 cash flow Disciplined OpEx breakeven expected grew sequentially Platform adoption is Improving use Momentum into t
Slide 10: Slide 10